|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 369.19 USD | +1.52% |
|
-3.94% | +12.80% |
| 02-12 | Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM | |
| 02-12 | European Commission approves Amgen's Uplizna® for generalized myasthenia gravis | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGEN INC. | Other Pharmaceuticals | +1.52% | -3.94% | +12.80% | +24.32% | +55.64% | 199B |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- AMGN Stock
- Charts Amgen Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition